Background: Diabetes is a complex metabolic disorder known to induce a high blood glucose level that fluctuates outside the normal range. Diabetes affects and damages the organs in the body and causes heart issues, blindness and kidney failure. Continuous monitoring is mandatory to keep the blood glucose level within a healthy range. Materials and Methods: This research was focused on diagnosing diabetes mellitus on zeolite nanoparticle-polyethylene glycol complex-immobilized interdigitated electrode sensor (IDE) surfaces. Zeolite nanoparticles were extracted from the fly ash of a thermal power plant by alkaline extraction. The surface morphology of the synthesized nanoparticles was observed by field-emission scanning electron microscopy and transmission electron microscopy, and the presence of certain elements and the particle size were determined by energy-dispersive X-ray spectroscopy and particle size analysis, respectively. Results: The crystalline PEG-zeolite nanoparticles were synthesized with a size of 40± 10 nm according to high-resolution microscopy. A particle size analyzer revealed the sizes of the fly ash and PEG-zeolite particles as 60± 10 μm and 50± 10 nm, respectively. The IDE surface was evaluated for its ability to display antifouling properties and sense glucose levels on the abovementioned nanoparticle-modified surface. Glucose oxidase was probed on the PEG-zeolite-modified IDE surface, and glucose was detected. PEG zeolite performed well with excellent antifouling properties on the IDE sensor surface and improved the glucose detection limit to 0.03 mg/mL from 0.08 mg/mL, as determined by linear regressions [y = 5.365x - 6.803; R² = 0.9035 (zeolite surface) and y = 5.498x + 5.914R² = 0.9061 (PEG-zeolite surface)]. This enhancement was ∼ 3-fold, and sensitivities were found to be 0.03 and 0.06 mg/mL glucose for the PEG-zeolite- and zeolite-modified surfaces, respectively, showing a 2-fold difference. Conclusion: The excellent biocompatible surface modified by PEG zeolite exhibited high performance and is useful for medical diagnosis.

Chronic obstructive pulmonary disease (COPD) is a common and frequently occurring disease that seriously endangers health, causing a heavy economic burden on patients and society. Acupuncture has been reported to have a therapeutic effect on patients with chronic obstructive pulmonary disease (COPD). However, compared with medications, it is difficult to identify a superior therapy. Therefore, the aim of this study was to evaluate the efficacy and safety of acupuncture, conventional drug and acupuncture plus conventional drug in the treatment of COPD. This was a multicenter, open-label randomized controlled trial (RCT) through a central randomization system. A total of 150 COPD patients were randomly assigned at a 1:1:1 ratio to the acupuncture group, conventional drug group or acupuncture plus conventional drug group for 12 weeks of treatment, followed by 12 weeks of untreated follow-up. The primary outcomes included the six-minute walk distance (6MWD) and St. George's Respiratory Questionnaire (SGRQ), and the secondary outcomes included the modified Medical Research Council dyspnea scale (mMRC), acute exacerbation, lung function, and quality of life (COPD assessment test). Statistical analysis was conducted via SPSS software (version 26.0). A total of 150 patients were included in the study, and 143 patients completed the trial. There were time effects, group effects and interaction effects in the three groups (P < 0.05). Compared with that in the conventional drug group, the 6MWD in the acupuncture plus conventional drug group increased significantly at 4, 8, and 12 weeks of treatment and at 12 weeks of follow-up. The difference was statistically significant (P < 0.05). The symptom scores, motor scores, impact scores and total SGRQ scores at different time points in the three groups tended to change with time, with a time effect (P < 0.05), and there was no group or interaction effect (P > 0.05). Among the secondary outcomes, there were time effects on the number of acute exacerbations, forced expiratory volume in one second (FEV1) and forced expiratory volume in one second/forced vital capacity (FEV1/FVC) at different time points in the three groups (P < 0.05). mMRC had time and group effects (P < 0.05). CAT had time effects, group effects and interaction effects (P < 0.05). Compared with the acupuncture group and the conventional drug group, the acupuncture plus conventional drug group was better at improving exercise ability, improving quality of life, and reducing dyspnea. It is safe and effective for the treatment of chronic obstructive pulmonary disease in the stable period, which can provide a reference for further related research. ClinicalTrials.gov, NCT03169504. Registered on 30 May 2017.

Chronic urticaria (CU) is characterized by persistent skin hives, redness, and itching, enhanced by immune dysregulation and inflammation. Our main objective is identifying key genes and molecular mechanisms of chronic urticaria based on bioinformatics. We used the Gene Expression Omnibus (GEO) database and retrieved two GEO datasets, GSE57178 and GSE72540. The raw data were extracted, pre‐processed, and analyzed using the GEO2R tool to identify the differentially expressed genes (DEGs). The samples were divided into two groups: healthy samples and CU samples. We defined cut‐off values of log ₂ fold change ≥1 and p < .05. Analyses were performed in the Kyoto Encyclopaedia of Genes and Genomes (KEGG), the Database for Annotation, Visualization and Integrated Discovery (DAVID), Metascape, Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and CIBERSOFT databases. We obtained 1613 differentially expressed genes. There were 114 overlapping genes in both datasets, out of which 102 genes were up‐regulated while 12 were down‐regulated. The biological processes included activation of myeloid leukocytes, response to inflammations, and response to organic substances. Moreover, the KEGG pathways of CU were enriched in the Nuclear Factor‐Kappa B (NF‐kB) signaling pathway, Tumor Necrosis Factor (TNF) signaling pathway, and Janus kinase/signal transducers and activators of transcription (JAK‐STAT) signaling pathway. We identified 27 hub genes that were implicated in the pathogenesis of CU, such as interleukin‐6 (IL‐6), Prostaglandin‐endoperoxide synthase 2 (PTGS2), and intercellular adhesion molecule‐1 (ICAM1). The complex interplay between immune responses, inflammatory pathways, cytokine networks, and specific genes enhances CU. Understanding these mechanisms paves the way for potential interventions to mitigate symptoms and improve the quality of life of CU patients.